RDUS News and Press, Radius Health Inc. From 07/07/22

Urges stockholders to vote “ FOR ” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWI...

Advances asset in the neuro-endocrine orphan disease space SCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced 30+ global sites are planned for the seamless Phase 2/3 pivotal trial Primary endpoint of hyperphagia supplemented by key seco...

NEW YORK, NY / ACCESSWIRE / June 28, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Health, Inc. (NASDAQ:RDUS)'s ...

Zendesk to be acquired by an investor group led by investment firms Permira and Hellman & Friedman in an all-cash transaction valued at approximately $10.2 billion. The price that Zendesk finally settled for was 40% below the midpoint of the original offer made by the same group o...

Earnings news gave a lift to a handful of stocks in Friday's midday action. CarMax (NYSE:KMX) and BlackBerry (BB) both showed strength after releasing their respective financial figures. Meanwhile, Wolfspeed (WOLF) also posted gains during intraday trading. An analyst upgrade encouraged inves...

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the ...

Shares of Radius Health (NASDAQ: RDUS) were up by more than 14.6% as of 12:28 p.m. on Thursday on news that the company has agreed to be acquired by a pair of private healthcare investment companies. The deal to take the business private is valued at $890 million, a sum to be split ...

The shares of Radius Health (NASDAQ:RDUS) surged 14% in the morning hours Thursday after the commercial stage biotech announced an agreement under which y Gurnet Point Capital and Patient Square Capital will acquire the company for $890M. The valuation includes the assumption of deb...

Transaction delivers immediate value and liquidity to Radius shareholders Result of nine-month strategic review process by the Radius Board to maximize shareholder value Potential per share value of $11.00, including $10.00 cash paid at closing and potential $1.00 CVR Repres...

Italian pharma giant Menarini Group and Radius Health (NASDAQ:RDUS) on Wednesday said they had submitted a new drug application to the U.S. FDA for their drug elacestrant to treat breast cancer. RDUS' elacestrant, which has been out-licensed to Menarini, is intended for the potentia...